Clinical Results: Safety and Efficacy

More than 30 studies have been performed to confirm the safety and efficacy of Bacillus subtilis DE111. A full genome sequencing confirmed the strain contained no plasmids, antibiotic resistant or deleterious genes. The genome sequence of DE111 has been uploaded to GenBank, the National Institutes of Health genetic sequence database.

Multiple human clinical studies support DE111’s benefits to digestive and immune health, and Deerland is committed to continuously conducting additional studies. All studies are IRB-approved, double-blind, randomized and placebo controlled.

 

Human Clinical Study: Supports Digestion

A clinical study evaluating the effect of DE111 on digestive health resulted in a significant influence on gut microflora measured prior to and after capsule consumption (5 billion CFU). Fecal samples showed an increase in the levels of B. subtilis and Bifidobacterium (good bacteria), and a slight decrease in levels of E. coli (bad bacteria). DE111 was also able to maintain healthy levels of cholesterol, glucose and triglycerides, indicating that DE111 supports the normal breakdown of complex carbohydrates, sugars and fats.

Human Clinical Study: Supports Regularity

A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64% in the DE111 group, while the proportion of normal stools decreased from 56% to 48% in the placebo group. In male participants specifically, the proportion of normal stools increased from 56% to 80%. In addition, a significant difference between the DE111 and placebo groups was observed in regards to normal and non-normal stool proportions in the 30+ age group. View Published Study – DE111

 


 

Human Clinical Study: Sports Performance, Body Composition and Recovery

In a study involving female collegiate athletes during offseason training, researchers found that DE111 (1 billion CFU), in conjunction with adequate post-workout nutrition, can improve body composition and indices of athletic performance. The results of the study showed that compared to the placebo, the probiotic DE111 produced statistically significantly improvements in the reduction of body fat percentage, and a strong trend indicating improved performance of the deadlift exercise.
View Published Study – DE111

In a study involving male collegiate athletes during offseason training, researchers found that DE111 (1 billion CFU), in conjunction with adequate post-workout nutrition, can promote tissue recovery and reduce likelihood of injury. The results of the study showed that compared to the placebo, the probiotic DE111 produced a statistically significantly reduction of tumor necrosis factor alpha (TNA-α).
View Published Study – DE111